Vinorelbine and Epirubicin for Metastatic Breast Cancer
Author Information
Author(s): Serin D, Verrill M, Jones A, Delozier T, Coleman R, Kreuser E-D, Mross K, Longerey B, Brandely M
Primary Institution: Institut Sainte Catherine
Hypothesis
Can an alternating regimen of oral and intravenous vinorelbine with epirubicin improve treatment convenience and efficacy for metastatic breast cancer?
Conclusion
The alternating regimen of oral and intravenous vinorelbine with epirubicin is effective and safe for treating metastatic breast cancer.
Supporting Evidence
- 25 responses were documented, yielding a response rate of 51%.
- Median progression-free survival was 8 months.
- Median overall survival was 20 months.
- Neutropenia was the main dose-limiting toxicity.
Takeaway
This study tested a new way to give chemotherapy for breast cancer that combines pills and injections, making it easier for patients.
Methodology
This was an open-label, multicentre phase II study where patients received a combination of intravenous vinorelbine and epirubicin on day 1 and oral vinorelbine on day 8 every 3 weeks.
Potential Biases
Potential bias due to the open-label design.
Limitations
The study was noncomparative and had a small sample size.
Participant Demographics
Median age of participants was 55 years, with 57% having received prior adjuvant chemotherapy.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI: 36–66
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website